A patient with gastric cancer with peritoneal carcinomatosis treated with intraperitoneal chemotherapy who survived more than 5 years receiving repeated laparoscopic examinations: a case report

Journal of Medical Case Reports

Toshiaki Watanabe²  Eiji Sunami²  Soichiro Ishihara²  Shinsuke Kazama²  Hiroaki Nozawa²  Keisuke Hata²  Kazushige Kawai²  Tomomichi Kiyomatsu²  Toshiaki Tanaka²  Junichiro Tanaka²  Takeshi Nishikawa²  Shigenobu Emoto²  Hironori Ishigami¹  Joji Kitayama²  Hironori Yamaguchi² 

[1]Department of Chemotherapy, The University of Tokyo, 7-3-1 Bunkyo-ku, Hongo, Tokyo 113-8655, Japan

[2]Department of Surgical Oncology, The University of Tokyo, 7-3-1 Bunkyo-ku, Hongo, Tokyo 113-8655, Japan

关键词: Paclitaxel;    Intraperitoneal infusions;    Gastric cancer;    Peritoneal carcinomatosis;    Laparoscopy;   

Others  :  1235826
DOI  :  10.1186/s13256-016-0799-5

 received in 2015-05-07, accepted in 2016-01-04,  发布年份 2016

【 摘 要 】

Background

Peritoneal dissemination of gastric cancer is still a dismal disease and has extremely poor prognosis even with systemic intensive chemotherapy. However, intraperitoneal chemotherapy using paclitaxel has recently shown good results. In order to perform optimal intraperitoneal chemotherapy, laparoscopic examination is necessary to assess the condition of peritoneal disseminated lesions. This is the first report of a case of a patient with gastric cancer with massive peritoneal metastasis treated with intraperitoneal administration of paclitaxel and repeated laparoscopic examinations who survived more than 5 years.

Case presentation

Here we report a case of a 60-year-old Japanese woman with peritoneal carcinomatosis of gastric cancer who underwent intraperitoneal chemotherapy receiving repeated laparoscopic examinations. The patient was referred to our institution for the treatment of peritoneal carcinomatosis of gastric cancer. The staging laparoscopy showed peritoneal metastasis in the whole peritoneal space with a peritoneal cancer index score of 23. An intraperitoneal access port was subcutaneously implanted. Paclitaxel was intraperitoneally and intravenously administered with oral administration of S-1. The second-look laparoscopy, which was performed after nine courses of intraperitoneal chemotherapy, revealed the disappearance of peritoneal carcinomatosis. A total gastrectomy with D2 lymphadenectomy was performed and intraperitoneal chemotherapy was continued after the surgery. The third laparoscopic examination, which was performed after 67 courses of intraperitoneal chemotherapy showed bilateral ovarian metastasis without recurrence of peritoneal carcinomatosis. Since multiple bone metastases developed after the third-look laparoscopy, bilateral adnexectomy was not performed and the chemotherapy was changed to the regimen including CPT-11. Our patient survived more than 5 years since the intraperitoneal chemotherapy started.

Conclusions

Sequential intraperitoneal chemotherapy could strongly suppress the development of peritoneal metastasis for several years. Repeated laparoscopic examinations are considered to be essential to evaluate the efficacy of intraperitoneal chemotherapy on peritoneal carcinomatosis of gastric cancer.

【 授权许可】

   
2016 Yamaguchi et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Ishigami H, Kitayama J, Otani K, Kamei T, Soma D, Miyato H, et al.: Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology. 2009, 76:311-14.
• [2]Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, et al.: Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010, 21:67-70.
• [3]Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H, Watanabe T: A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer. 2013, 119:3354-8.
• [4]Kitayama J, Ishigami H, Yamaguchi H, Yamashita H, Emoto S, Kaisaki S, et al.: Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. Ann Surg Oncol. 2014, 21:539-46.